The continuous presentation was accepted under the provisional order of the Minister of Health which allows corporations to submit knowledge and data on protection and effectiveness as they become available. Often called an ongoing review, this allows Health Canada to begin its review immediately, as data continues to arrive Health Canada will not authorize an ongoing review vaccine until it has obtained mandatory evidence to help protect, efficacy and quality. After the approval of any vaccine presentation, Health Canada will publish the evidence you have reviewed to make your resolution transparency.
The BNT162b2 candidate vaccine is based on BioNTech’s patented mNR generation and is supported by Pfizer’s global vaccine production and progression capabilities. Encodes an optimized full duration of SARS-CoV-2 glucoprotein (S), which is a target of virus neutralizing antibodies. The candidate vaccine is recently being evaluated as a component of an ongoing Phase 3 global exam at more than 120 clinical sites worldwide. To date, the trial has recruited approximately 37,000 participants, more than 28,000 of whom have won their immediate vaccination.
SOURCE Pfizer Canada Inc.